Translation of "Vaccin sous-unité " (French → English) :

vaccine using antigenic subunits

non-infectious subunit viral vaccine

split influenza virus vaccine

Short stature due to primary acid-labile subunit (ALS) deficiency is characterized by moderate postnatal growth deficit, markedly low circulating levels of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3

Beta subunit

system subunit

Question No. 446 Ms. Kirsty Duncan: With respect to the current pandemic of new influenza A (H1N1): (a) what is the key leadership shown by the organizational reporting chart, from the two lead ministries, the Public Health Agency of Canada and Public Safety Canada, through to the deputy ministers; (b) what is the decision-making process to determine which of the two ministries leads on issues; (c) what, if any, funding requests have been made by government departments for pandemic planning since the beginning of the pandemic in Canada; (d) what, if any, additional funding is required to ensure all government departments have tested their H1N1 plans and rolled them out to their employees; (e) what, if any, specific agreements have been ...[+++]signed with the provinces and territories, and which, if any, agreements still need to be signed; (f) what are the government’s identified critical services, what is the decision-making process to reduce services if required, and who has responsibility for these decisions; (g) how will the government acquire and distribute medical countermeasures if required; (h) what guidance is being provided to foreign missions, including consulates, embassies, high commissions and trade offices, and what is the decision-making process to reduce services, or repatriate staff; (i) what guidance is being provided to the Canadian Forces, including the army, the air force and the navy, and what recommendations are being made for military personnel; (j) with regard to recommendations being made to the Canadian Forces and military personnel concerning vaccinations, what processes are in place to (i) re-evaluate policies as required, (ii) ensure legal compliance and respect ethical considerations, (iii) ensure protection of our troops in Afghanistan; (k) on what date was the pandemic vaccine ordered, and what, if any, effect did having only one supplier, or the decision to use adjuvant, had on the delivery date for the H1N1 vaccine; (l) what, i ...

(Return tabled) Question No. 425 Ms. Kirsty Duncan: With respect to the current pandemic of new influenza A (H1N1): (a) who is at the top of the pandemic organizational chart for the country; (b) what gaps still exist in the government’s overarching plan, recognizing that it is an ever-evolving plan, and by what date will identified gaps be addressed; (c) what money remains from the $400 million contained in the budget of 2006 as ‘to be set aside as a contingency to be accessed on an as-needed basis’; (d) what funds have been spent since the start of the pandemic in Canada to address response, specifically, (i) what government departments have tested their pandemic plan, (ii) what departments operationalized their plans or part of their ...[+++]plans in the spring, and updated their plans since the lessons learned from the spring; (e) should there be an election, what is the pandemic preparedness plan for Elections Canada, both to protect the health and well-being of its employees and Canadians; (f) what are the outstanding issues among medical personnel in terms of preparedness, and how are these issues being addressed; (g) what was the process for monitoring swine herds prior to April 24, 2009, and how has it increased since that date; (h) what is the purpose behind the absence of a Canadian notifiable swine influenza surveillance system; (i) what is known of the clinical spectrum of the disease at this time, and what are the possible long-term impacts on lungs, and other organs, and potential long-term costs to the healthcare system; (j) by what date are provincial and territorial vaccine distribution plans to be in place, what oversight exists to ensure they are in place, and will they be made public; (k) what contingency plans are being put in place should Canadian distributors run out of stock of N95 masks; (l) will there be a compensation package should there be challenges with the vaccine; (m) what recommendations are being made to those with chronic con ...

The Commission has started to work on the enhancement of its crisis-management tools, such as a situation-awareness platforms for decision makers known as HEDIS (Health Emergency and Diseases Information System) and its existing Early Warning and Response System; The Commission has set up its interdepartmental crisis coordination unit which would become operational in the event of a crisis such as a pandemic; Commissioner Kyprianou is liaising between Member States and the pharmaceutical industry on questions relating to the production, distribution and supply of antivirals and vaccines; Following the informal Health Council meeting ...[+++]in Vienna on February 24 , the Commission and ECDC are now coordinating a network of Member States’ press officers, in order to ensure the communication of clear and accurate messages to the public throughout Europe; Pandemic preparedness plans will be reviewed again at a meeting of the Commission, Member States and WHO hosted by the European Centre for Disease Prevention and Control in Stockholm on 3 May and follow-up by Member States of lessons learned during the exercise will be discussed in June; Workshops to share best practice on issues such as public health interventions, business continuity planning, border controls and quarantine will be held; The Commission will start improving the coordination mechanism through training and role play between involved bodies and plans to run further exercises.

' ( C ) ALL THE BOVINE ANIMALS SATISFY THE CONDITIONS LAID DOWN IN 1 ( B ) AND ( C ); HOWEVER , THE BOVINE ANIMALS UNDER 30 MONTHS OLD WHICH HAVE BEEN VACCINATED WITH LIVE BUCK 19 VACCINE MAY SHOW A BRUCELLA COUNT EQUAL TO OR HIGHER THAN 30 I. U . OF AGGLUTINATION PER MILLILITRE BUT LOWER THAN 80 I. U . OF AGGLUTINATION PER MILLILITRE PROVIDED THAT , WHEN THE COMPLEMENT FIXATION REACTION IS TESTED , THEY SHOW :